Abstract
Intellectual disability (ID) has emerged as the commonest manifestation of underlying genomic abnormalities. Given that molecular genetic tests for diagnosis of ID usually require high costs and yield relatively low diagnostic rates, identification of additional phenotypes or comorbidities may increase the genetic diagnostic yield and are valuable clues for pediatricians in general practice. Here, we enrolled consecutively 61 children with unexplained moderate or severe ID and performed chromosomal microarray (CMA) and sequential whole-exome sequencing (WES) analysis on them. We identified 13 copy number variants in 12 probands and 24 variants in 25 probands, and the total diagnostic rate was 60.7%. The genetic abnormalities were commonly found in ID patients with movement disorder (100%) or with autistic spectrum disorder (ASD) (93.3%). Univariate analysis showed that ASD was the significant risk factor of genetic abnormality (Pā=ā0.003; OR 14, 95% CI 1.7ā115.4). At least 14 ID-ASD associated genes were identified, and the majority of ID-ASD associated genes (85.7%) were found to be expressed in the cerebellum based on database analysis. In conclusion, genetic testing on ID children, particularly in those with ASD is highly recommended. ID and ASD may share common cerebellar pathophysiology.
Similar content being viewed by others
Introduction
Intellectual disability (ID) is a disability of intellectual and adaptive functions1. Deficits in intellectual functions include reasoning, problem solving, planning, abstract thinking, judgment, academic learning, and learning from experiences. Deficits in adaptive function mean failure to meet developmental and sociocultural standards for personal independence and social responsibility1. It is an important medical issue in the child development. In early childhood, the diagnosis of ID is based on documented substantial developmental delays (DD), including motor, cognitive, and speech delays. The world-wide prevalence of DD/ID is 1.5ā3%2,3.
Underlying causes of DD/ID are very diverse, including brain malformation, metabolic disorders, brain traumatic injury, vascular disorders, nervous system infection, genetic abnormalities or even environmental factors2,3,4. Along with advancement in biomolecular knowledge, we become aware that the genetic contribution to DD/ID is ever more significant than previously thought and thus DD/ID itself has emerged as the commonest phenotypic manifestation of underlying genomic abnormalities5,6. Knowing the genetic etiology for DD/ID may help confirm the diagnosis that requires specific treatment and may also relieve uncertainty, improve the understanding of prognosis, and anticipate and manage associated medical and behavioral problems. Moreover, genetic diagnosis facilitates counseling, cascade testing and pre-natal testing where appropriate7. Thus, genetic testing is crucial for DD/ID children with unexplained etiology.
With the rapid development of next generation sequencing (NGS) technology, all kinds of disease-causing mutations, such as SNVs (single nucleotide variants), Indel (small insertion/deletion) and CNVs (copy number variants), can be detected rapidly and efficiently8. Recent reports showed that the genetic diagnostic rate in severe DD/ID patients is only around 12ā20.8% based on chromosomal microarray (CMA), and 16ā45% based on whole-exome sequencing (WES)9,10,11. Thus nearly half of DD/ID children remain undiagnosed despite the available CMA and WES tests. Children with DD/ID are at an increasing risk for a variety of comorbidities, including growth failure, epilepsy, ASD, ADHD, psychiatric illness, sensory (vision and hearing) impairments, skeletal issues and endocrine/metabolic dysfunctions12. It is therefore hypothesized that children with DD/ID are likely to have underlying genetic causes if they are also presenting additional phenotypes/comorbidities. High costs and relatively low diagnostic rates often result from advanced genetic testing; therefore, additional phenotypes or comorbidities which are associated with genetic abnormalities can increase the genetic diagnostic yield in affected DD/ID patients are valuable clues for pediatricians in general practice.
In our study, we used a sequential diagnostic scheme combining CMA and WES to conclude the genetic diagnosis in a group of moderate to severe DD/ID patients with unexplained etiology, and the risk phenotypes or comorbidities for genetic abnormalities were analyzed.
Results
Demographics of the study population
The present study recruited a total of 61 ID/DD patients with 37 (60.7%) males. The age at the time of enrollment ranged from 3 to 18Ā years (median, 6Ā years). The spectrum of additional phenotypes or comorbidities was listed at Table 1. About 77% of the enrolled patients displayed failure to thrive or short stature, 52.5% with microcephaly, 26.2% with facial dysmorphism, 36.1% with epilepsy, 34.4% with hypotonia and 24.6% with autism. Congenital abnormalities of internal organs involving heart, kidney or gastrointestinal tract accounted for 8ā10% of the enrolled patients (Table 1).
Causative genetic variants in DD/ID patients
In 12 out of all 61 probands, CMA identified clinically significant 13 CNVs that were consistent with their phenotypes (Supplementary Table 1). The genetic diagnostic rate based on CMA was 19.7%. The other 49 patients with negative CMA results then underwent WES analysis. We further identified 24 variants in 25 probands (Supplementary Table 2). The 24 variants found in 18 genes included 8 pathogenic and 2 uncertain variants reported in ClinVAr, and 14 novel variants. Of the 14 novel variants, six truncating variants were classified as pathogenic, and 8 missense variants were either classified as pathogenic (nā=ā3) or likely pathogenic variants (nā=ā5) according to ACMG/AMP guidelines13. The overall genetic diagnostic rate using CMA and WES analysis was 60.7%.
Risk factors of genetic abnormalities in DD/ID patients
Among the individuals having associated phenotypes and comorbidities, genetic abnormalities were most likely to be found in DD/ID patients with movement disorder (100%) or with ASD (93.3%; Table 1). Further risk analysis showed that there was no predicted risk associated with CNVs, but ASD was a factor highly associated with nucleotide variation (Pā=ā0.002; OR 18.1, 95% CI 2.1ā155.5) and overall genetic abnormalities (Pā=ā0.003; OR 14, 95% CI 1.7ā115.4; Table 2). In contrast, microcephaly, short stature, facial dysmorphism as well as movement disorder were not significantly associated with genetic abnormalities.
ASD-associated genes in DD/ID patients
Of all 61 study patients, 14 out of 15 patients who had ASD were found to have genetic abnormalities including 3 CNVs and 11 nucleotide variations (Table 3). The regions of the 3 CNVs are located in chromosome Xp22.31, 15q11.2ā13.1 and 17p11.2, and harbored genes associated with neurological diseases including GABRB3, UBE3A, MAGEL2, RAI1, ALDH3A2, ATPAF2 according to the database of Online Mendelian Inheritance in Man (OMIM). The 11 nucleotide variations involve genes including KDM5C, BRAF, KIF1A, IQSEC2, KMT2A, MECP2, SON, and DYRK1A. Among these genes, the most common gene harboring abnormalities was KDM5C that had been found in 3 patients, followed by KMT2A found in 2 patients. The tissue expression and biological functions of these ASD-associated genes in DD/ID patients were listed in Table 4. All of these 14 ASD-associated genes found in our DD/ID patients could be expressed in the central nerve system based on the GTEx database. Interestingly, we found that the majority of these genes (12/14) expressed in the cerebellum and a few are expressed in the frontal cortex and hypothalamus. The biological functions of these genes are involved in the transcriptional regulation, neurotransmission, cell proliferation, metabolism and protein stability, and all were essential for cellular homeostabsis in the central nervous system.
Discussion
Our research approach, which involved phenotyping, CMA and WES on the samples obtained from 61 consecutively enrolled probands with DD/ID with unexplained etiology, provided a diagnostic yield of 60.7%. Our diagnostic rate exceeds that of most published studies9,10,11. Totally, 13 CNVs (including 3 novel CNVs) and 24 nucleotide variations (including 14 novel variants) were revealed. We have provided information on variants that were possibly pathogenic in these genes based on available genetic evidence according to ACMG guidelines. Among these patients, we found overall genetic abnormalities were most likely to be found in the DD/ID patients with movement disorder or with ASD. Further univariate analysis showed ASD was a significant risk factor/comorbidity linked to genetic abnormalities in DD/ID patients with unexplained etiology and the genetic diagnostic rate was up to 93.3% in DD/ID patients with ASD. The biological functions of these ASD-DD/ID associated genes involved variable cellular functions in the central nerve system and the expression of these genes was mainly in the cerebellum.
Establishing a diagnosis of DD/ID children is critical for accurate health surveillance and further care planning for the affected individuals, especially for those with moderate-to-severe impairment. However, the etiology of DD/ID is very extensive and diverse2,3,4. Thus, to identify an etiology in DD/ID children is a challenge to clinicians, particularly in those who failed to obtain a diagnosis despite using the suggested stepwise systemic clinical evaluations10,12,14. The rapid development of NGS technology makes molecular genetic tests available in clinical practice, but its cost may not be affordable for most families. Children with DD/ID are at an increased risk for a variety of comorbidities, including growth failure, epilepsy, autistic spectrum disorder, attention deficits and hyperactivity disorder, psychiatric illness, sensory (vision and hearing) impairments, skeletal issues and endocrine/metabolic dysfunctions12. From these comorbidities, our study found that ASD was a risk factor/comorbidity associated with genetic abnormalities in DD/ID patients with unexplained etiology and the genetic diagnostic rate was up to 93.3% in DD/ID patients with ASD. Thus, genetic survey was deemed critical and should be highly encouraged in moderate to severe DD/ID children who also had the comorbidity of ASD.
Among the DD/ID children with ASD, we found multiple genetic variants in at least 11 ASD-DD/ID associated genes. The abnormalities of KDM5C and KMT2A genes were found in more than two patients. Interestingly, both genes are chromatin regulators and abundantly expressed in the brain15,16. KDM5C encodes a histone demethylase and KMT2A encodes a histone methyltransgerases15,16. KDM5C knockout mice as well as KMT2A knockout mice both exhibited abnormal social behavior including aggression, impaired learning and memory15,16. Chromatin stability and flexibility rely on dynamic regulations and are crucial for neuronal circuitries, synaptic plasticity and the development of the nervous system17. Dysregulation of chromatin regulation caused cognitive deficits and autistic behaviors17. In a most recent study, Satterstrom et al. sequenced 35,584 samples including 11,986 with ASD and identified 102 ASD-associated genes18. Among these 102 ASD-associated genes, 49 genes were associated with DD/ID and had more disruptive de novo variants than ASD-associated genes without DD/ID. Three ASD-DD/ID associated genes in our study (GABRB3, RAI1, and DYRK1A) were also revealed in Satterstrom et al. study18. The GABAAR Ī²3 subunit (encoded by GABRB3) is important for type A Ī³-Aminobutyric acid (GABAA) receptor assembly, emerges at embryonic stage in the whole brain and reaches its strongest expression at the perinatal stage19. RAI1 encodes a transcriptional factor implicated in embryonic neurodevelopment, neuronal differentiation, cell growth and cell cycle regulation20. DYRK1A involves in neurogenesis, neuronal differentiation and dendrite formation during brain development21,22. Other ASD-DD/ID associated genes noted in our study also expressed in the brain and involved in the neurophysiology. Thus, cognitive deficits (DD/ID) and ASD are likely to be biochemically and molecularly related, and share common neuropathophysiology.
Based on the GTEx database, we found that the majority of ASD-DD/ID associated genes in our study are highly expressed in the cerebellum, and two in the frontal cortex. This finding indicates the significant role of cerebellum in the neuropathophysiology of DD/ID and ASD. In addition to neocortex, evidence obtained from clinical and neuroimaging studies has shown that cerebellum are involved in a series of cognitive functions23,24,25. Functional Magnetic Resonance Imaging studies showed that cognitive tasks of language, visual, spatial, executive and working memory can trigger cerebellar activation26. Lesions confined to the cerebellum result in cerebellar cognitive affective syndrome, the hallmark features of which include clinically relevant deficits in executive function, visual spatial performance, linguistic processing and dysregulation of affect. The affective dysregulation of autism spectrum disorder was manifested in deficits in emotional control, attentional control and social skills27. Moreover, hypoplasia or volume decreases in the cerebellar vermis was often identified in ASD children, and a correlation was found between these changes and the severity of behavioral and cognitive deficits, which include impairment social interaction, communication and increased repetitive behaviors28. Our findings were also supported by several computational studies using aggregated gene expression patterns to demonstrate that ASD susceptibility genes showed high coexpression in two distinct regions during brain development: the frontal/somatomotor neocortex and the cerebellar cortex29,30.
The relatively high diagnostic yield that we reported here may stem from the restrict inclusion criterion of moderate to severe DD/ID. Moreover, small case numbers in our cohort may lead to type I error and the wide 95% CI of the data in our subgroup analysis (Tables 1 and 2) impose a degree of uncertainty. Further studies recruiting a larger number of DD/ID patients will be necessary to validate our findings. Studies to validate or rule out causality of the candidate novel variants found in our study are ongoing. In conclusion, a sequential diagnostic scheme combining CMA and WES is useful to confirm the genetic diagnosis in a group of moderate to severe DD/ID patients with unexplained etiology. ASD was a risk factor/comorbidity associated with genetic abnormalities and increased the genetic diagnostic yield. Moreover, the ASD-DD/ID associated genes are highly expressed in the cerebellum, suggesting a role of cerebellum in the neuropathophysiology of DD/ID and ASD.
Methods
Study population
We enrolled consecutive 61 patients who aged below 18Ā years old and was diagnosed as moderate or severe DD/ID with unexplained etiology at our hospital, a tertiary referral medical center in Southern Taiwan, from Feb 2018 to Dec 2019. Moderate or severe DD/ID was defined by a performance score at least two standard deviations below the mean for an appropriate tests, including the Bayley Scales of Infant Development (BSID-III), or Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV), etc.2,3. All medical records and laboratory results, especially MR neuroimages and metabolic disorder surveys, were reviewed. Each enrolled patient was assessed in our pediatric department by a pediatric neurologist for detailed neurological examination and a pediatric geneticist for identification of facial dysmorphism or other phenotypes. Unexplained DD/ID was diagnosed when there was no any defined etiology of DD/ID after detailed clinical evaluation and available laboratory/imaging investigations. DD/ID patients with any possible known etiology were excluded. This study was approved by the ethics committee at National Cheng Kung University Hospital, and the parents of all patients in this study provide written informed consent. All the methods were carried out in accordance with the relevant guidelines and regulations.
Covariates/comorbidities/phenotypes
Short stature refers to a body height which is more than two standard deviations below the mean for children of that same-sex and chronologic age, while failure to thrive refers to a weight for age that falls below the 5th percentile on multiple occasions or weight deceleration that crosses two major percentile lines on a growth chart31,32. Microcephaly is defined as a head circumference more than two standard deviations below the mean for gender and age33. When autistic trait or attention-deficit hyperactivity disorder (ADHD) was suspected during the assessments by psychologists, additional tests such as Continuous Performance Tests, Standard Version of the Childhood Autism Rating ScaleāSecond Edition or Social Communication Questionnaire were performed34,35. Diagnosis of autistic spectrum disorder (ASD) or ADHD was further confirmed by certificated pediatric psychiatrists based on the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V)36.
CMA and WES analysis and validation
Genomic DNA was isolated from blood of all study patients and their parents with the use of a FavorPrep Nucleic Acid Extraction kit and was stored at āĀ 20Ā Ā°C. All patients underwent CMA analysis first. WES was further tested to detect nucleotide variants in those who had negative results on CMA (Fig.Ā 1).
For CMA analysis, all samples were screened using the CytoOneArray chromosomal DNA microarray (Phalanx Biotech group Inc., Taiwan, ROC). The resolution of this microarray is nearby 30Ā Kb, especially focused on disease-related genes. The experimental processes were executed by Phalanx service laboratory which was certificated by ISO17025CNVs calling were obtained by using circular binary segmentation (CBS) algorithm which are conducted by the function of MATLAB version R2009a (Math Works Inc.). Following the ACMG guidance for copy-number variation (CNV), the detected CNVs were interpreted according to whether the CNVs were pathogenic or benign in the scientific literature, general genome databases, integrated databases, and curated databases, including UCSC Genome Browser website, OMIM, ClinGen Dosage Sensitivity Map, dbVar database, Database of Genomic Variants, International Standards for Cytogenomic Arrays Consortium Database and DECIPHER37,38.
For WES, exomes were enriched with the use of a SeqCap EZ MedExome Target Enrichment Kit (Roche Sequencing, USA). The enriched DNA samples were sequenced by 2āĆā150 paired-end sequencing using the nextseq500 high output sequencing system (Illumina, USA) to produce raw data. The paired-end sequence reads obtained from Illumina NovaSeq 6000 platform were filtered and trimmed to retrieve high-quality reads. After processing alignment, quality check, variant calling, annotation, and prioritization, we classified the candidate variants as pathogenic, likely pathogenic, uncertain significance, and benign, according to the guidelines from the ACMG. Candidate pathogenic or likely pathogenic variants were scrutinized for genotype to phenotype analysis and manually reviewed by using ClinVar and OMIM database13,39. The final diagnosis or causative variants was confirmed using Sanger sequencing.
Tissue expression of disease associated genes was assessed using publicly available data on the GTEx database (www.gtexportal.org), and the biological function of disease associated genes was obtained from the UniProt database (www.uniprot.org).
Statistics
In order to identify the predictive factors of the genetic diagnostic yield, we compared differences in yield rate between the presence and absence of certain demographic and clinical factors using the Fisher exact test. Further, potential predictors with Pā<ā0.05 in the univariate analysis or clinically significant variables were included in a multivariate logistic regression model. Adjusted odds ratios (ORs) and associated 95% confidence intervals (CIs) were computed. All analyses were performed on SPSS (version 20.0; SPSS Institute, Chicago, IL, USA).
References
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edn. (APA Press, 2013).
Moeschler, J. B. & Shevell, M. Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics 134, e903āe918 (2015).
de Ligt, J. et al. Diagnostic exome sequencing in persons with severe intellectual disability. N. Engl. J. Med. 367, 1921ā1929 (2012).
Kuo, H. T., Muo, C. H., Chang, Y. T. & Lin, C. K. Change in prevalence status for children with developmental delay in Taiwan: A nationwide population-based retrospective study. Neuropsychiatr. Dis. Treat. 11, 1541ā1547 (2015).
Grozeva, D. et al. Targeted next-generation sequencing analysis of 1,000 individuals with intellectual disability. Hum. Mutat. 36, 1197ā1204 (2015).
Ropers, H. H. Genetics of early onset cognitive impairment. Ann. Rev. Gen. Hum. Genet. 11, 161ā187 (2010).
Foo, Y. L. et al. Genetic evaluation of children with global developmental delay: Current status of network systems in Taiwan. Pediatr. Neonatol. 56, 213ā219 (2015).
Liu, Y. et al. Targeted next-generation sequencing for clinical diagnosis of 561 mendelian diseases. PLoS ONE 10, e0133636 (2015).
Gilissen, C. et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 511, 344ā347 (2014).
Han, J. Y. & Lee, I. G. Genetic tests by next generation sequencing in children with developmental delay and/or intellectual disability. Clin. Exp. Pediatr. 63, 195ā202 (2020).
Ezugha, H. et al. Microarray analysis in children with developmental disorder or epilepsy. Pediatr. Neurol. 43, 391ā394 (2010).
Srour, M. & Shevell, M. Genetics and the investigation of developmental delay/intellectual disability. Arch. Dis. Child. 99, 386ā389 (2014).
Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405ā424 (2015).
Miller, D. T. et al. Consensus statement: Chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am. J. Hum. Genet. 86, 749ā764 (2010).
Iwase, S. et al. A mouse model of X-linked intellectual disability associated with impaired removal of histone methylation. Cell Rep. 14, 1000ā1009 (2016).
Kerimoglu, C. et al. KMT2A and KMT2B mediate memory function by affecting distinct genomic regions. Cell. Rep. 20, 538ā548 (2017).
Ronan, J. L., Wu, W. & Crabtree, G. R. From neural development to cognition: Unexpected roles for chromatin. Nat. Rev. Genet. 14, 347ā359 (2013).
Satterstrom, F. K. et al. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell 180, 568ā584 (2020).
Laurie, D. J., Wisden, W. & Seeburg, P. H. The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J. Neurosci. 12, 4151ā4172 (1992).
Falco, M., Amabile, S. & Acquaviva, F. RAI1 gene mutations: Mechanisms of SmithāMagenis syndrome. Appl Clin. Genet. 10, 85ā94 (2017).
Tejedor, F. J. & HƤmmerle, B. MNBāDYRK1A as a multiple regulator of neuronaldevelopment. FEBS J. 278, 223ā235 (2011).
Dang, T. et al. Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development. Mol. Psychiatry. 23, 747ā758 (2018).
Schmahmann, J. D. & Sherman, J. C. The cerebellar cognitive affective syndrome. Brain 121, 561ā579 (1998).
Grimaldi, G. & Manto, M. Topography of cerebellar deficits in humans. Cerebellum 11, 336ā351 (2012).
Donovan, A. P. & Basson, M. A. The neuroanatomy of autism: A developmental perspective. J. Anat. 230, 4ā15 (2017).
Stoodley, C. J., Valera, E. M. & Schmahmann, J. D. Functional topography of the cerebellum for motor and cognitive tasks: An fMRI study. Neuroimage 59, 1560ā1570 (2012).
Schmahmann, J. D. The cerebellum and cognition. Neurosci. Lett. 688, 62ā75 (2019).
DāMello, A. M., Crocetti, D., Mostofsky, S. H. & Stoodley, C. J. Cerebellar gray matter and lobular volumes correlate with core autism symptoms. Neuroimage Clin. 7, 631ā639 (2015).
Willsey, A. J. et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell 155, 997ā1007 (2013).
Parikshak, N. N. et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell 155, 1008ā1021 (2013).
Wilkes, M. S. & Anderson, M. A primary care approach to adolescent health care. West J. Med. 172, 177ā182 (2000).
Gonzalez-Viana, E., Dworzynski, K., Murphy, M. S. & Peek, R. Faltering growth in children: Summary of NICE guidance. BMJ 358, 4219 (2017).
Passemard, S., Kaindl, A. M. & Verloes, A. Microcephaly. Handb. Clin. Neurol. 111, 129ā141 (2013).
Berger, I., Slobodin, O. & Cassuto, H. Usefulness and validity of continuous performance tests in the diagnosis of attention-deficit hyperactivity disorder children. Arch. Clin. Neuropsychol. 32, 81ā93 (2017).
Schopler, E., Van Bourgondien, M., Wellman, G. & Love, S. Childhood Autism Rating Scale-Second Edition (CARS2): Manual (Western Psychological Services, 2010).
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th edn, 85ā93 (American Psychiatric Association, 2000).
Hamosh, A., Scott, A. F., Amberger, J. S., Bocchini, C. A. & McKusick, V. A. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33, D514-517 (2005).
South, S. T., Lee, C., Lamb, A. N., Higgins, A. W. & Kearney, H. M. ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013. Genet Med 15, 901ā909 (2013).
Tarailo-Graovac, M. et al. Exome sequencing and the management of neurometabolic disorders. N. Engl. J. Med. 374, 2246ā2255 (2016).
Acknowledgements
We express our gratitude to the patients, their caretakers, and the clinical and laboratory staff from National Cheng Kung University Hospital.
Funding
This study was supported by grants from National Cheng Kung University Hospital (NCKUH-10802015) and the Taiwan Taiwan National Science Council (MOST 106-2314-B-006-075, and 108-2314-B-006-066). The funder did not participate in the work.
Author information
Authors and Affiliations
Contributions
Study concept and design: all authors. Data collection: all authors. Data analysis: J.S.C. and M.C.T. Manuscript drafting: J.S.C., W.H.Y. and Y.F.T. Study supervision: Y.F.T. All authors critically reviewed the manuscript and agreed on this final version to be submitted to the journal.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chen, JS., Yu, WH., Tsai, MC. et al. Comorbidities associated with genetic abnormalities in children with intellectual disability. Sci Rep 11, 6563 (2021). https://doi.org/10.1038/s41598-021-86131-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-021-86131-3
This article is cited by
-
Roles of KCNA2 in Neurological Diseases: from Physiology to Pathology
Molecular Neurobiology (2024)
-
Single-cell epigenomics and spatiotemporal transcriptomics reveal human cerebellar development
Nature Communications (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.